Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials

Alfonso Piciocchi, Monica Messina, Marta Cipriani, Francesca Paoloni, Giorgia Simonetti, Raffaele Palmieri, Giovanni Marconi, Francesco Buccisano, Paola Fazi, Marco Vignetti, Giovanni Martinelli, Adriano Venditti

Blood (2022) 140 (Supplement 1): 137–138.

https://doi.org/10.1182/blood-2022-158890

Published: 2022

Journal Articles

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1705–1707.

https://doi.org/10.1182/blood-2022-157393

Published: 2022

Journal Articles

Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party

Blood (2019) 134 (Supplement_1): 2931.

https://doi.org/10.1182/blood-2019-125052

Published: 2019

Journal Articles

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

Irene Della Starza, PhD, Lucia Anna De Novi, PhD, Alessandra Santoro, PhD, Salemi Domenico, PhD, Marzia Cavalli, PhD, Roberta Soscia, Francesca Paoloni, Lucia Menale, Valerio Apicella, Caterina Ilari, PhD, Antonella Vitale, Marco Vignetti, MD, Renato Bassan, MD, Sabina Chiaretti, MD PhD, Anna Guarini, PhD, Robin Foà, MD

Blood (2018) 132 (Supplement 1): 2828.

https://doi.org/10.1182/blood-2018-99-118219

Published: 2018

Journal Articles

Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study)

Blood (2018) 132 (Supplement 1): 1135.

https://doi.org/10.1182/blood-2018-99-113314

Published: 2018

Journal Articles

Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study

Giuseppe Rossi, Doriana Gramegna, Francesca Paoloni, Bruno Fattizzo, Francesca Binda, Mariella D’Adda, Mirko Farina, Elisa Lucchini, Francesca Romana Mauro, Flavia Salvi, Monia Marchetti, Paola Fazi, Francesco Zaja, Wilma Barcellini

Blood (2018) 132 (5): 547–550.

https://doi.org/10.1182/blood-2018-03-835413

Published: 2018

Journal Articles

Short Course of Bortezomib in Anemic Patients with Refractory or Relapsed Cold Agglutinin Disease. a Phase II Prospective Study By the Gimema Group

Giuseppe Rossi, MD, Francesca Paoloni, Bruno Fattizzo, MD, Francesca Binda, MD, Mariella D'Adda, MD, Mirko Farina, MD, Cecilia Carbone, MD, Francesco Zaja, MD, Elisa Lucchini, MD, Francesca Romana Mauro, MD, Flavia Salvi, MD, Monia Marchetti, MD, Paola Fazi, Wilma Barcellini, MD

Blood (2017) 130 (Supplement 1): 2199.

https://doi.org/10.1182/blood.V130.Suppl_1.2199.2199

Published: 2017

Journal Articles

Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms

Blood (2015) 126 (23): 2821.

https://doi.org/10.1182/blood.V126.23.2821.2821

Published: 2015

Journal Articles

Autopsy Analysis On Epidemiology and Site of Involvement Of Invasive Fungal Infections (IFI) In Hematological Malignancies : A Retrospective Study at Hematologic Tertiary Care Department

Anna Chierichini, Francesca Monardo, Barbara Anaclerico, Paola Anticoli Borza, Velia Bongarzoni, Domenico Campagna, Michele Cedrone, Susanna Fenu, Marianna Norata, Francesca Paoloni, Benedetto Ronci, Luciana Annino

Blood (2013) 122 (21): 5589.

https://doi.org/10.1182/blood.V122.21.5589.5589

Published: 2013

Journal Articles

Clinical Relevance of an Extended Diagnostic Work-Out in Patients with Primary Autoimmune Amolytic Anemia (AIHA)

Francesca R Mauro, MD, PhD, Daniele Armiento, MD, Serelina Coluzzi, MD, Maria S De Propris, PhD, Francesca Paoloni, BS, Gianluca Giovannetti, MD, Matteo Molica, MD, Luisa Quattrocchi, MD, Michelina Santopietro, MD, Chiara Spadafora, Lucia Granati, MD, Mara Riminucci, MD, Anna Guarini, PhD, Gabriella Girelli, MD, Robin Foà, MD

Blood (2012) 120 (21): 3192.

https://doi.org/10.1182/blood.V120.21.3192.3192

Published: 2012

Journal Articles

Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression

Francesca R Mauro, MD, PhD, Mara Riminucci, MD, Davide Rossi, MD, PhD, Francesca Paoloni, BS, Luca Laurenti, MD, Anna M Frustaci, MD, Giuseppe Cimino, MD, Michelina Santopietro, MD, Chiara Spadafora, Angela Rago, M.D., Francesco Autore, MD, Molica Matteo, MD, Brocchieri Simonetta, MD, Emanuele Nicolai, MD, Gianluca Gaidano, MD, PhD, Anna Guarini, PhD, Bianco Paolo, MD, Robin Foà, MD

Blood (2012) 120 (21): 3888.

https://doi.org/10.1182/blood.V120.21.3888.3888

Published: 2012

Journal Articles

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Blood (2011) 118 (25): 6521–6528.

https://doi.org/10.1182/blood-2011-05-351403

Published: 2011

Journal Articles

ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112

Ilaria Iacobucci, PhD, Federica Cattina, MD, Silvia Pomella, Annalisa Lonetti, Anna Ferrari, Cristina Papayannidis, Stefania Trino, Daniela Erriquez, Viviana Guadagnuolo, Emanuela Ottaviani, Serena Formica, Simona Soverini, Francesca Paoloni, Marco Vignetti, Domenico Russo, Giovanni Perini, Michele Baccarani, MD, Giovanni Martinelli, MD

Blood (2011) 118 (21): 2574.

https://doi.org/10.1182/blood.V118.21.2574.2574

Published: 2011

Journal Articles

The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients

Ilaria Iacobucci, Anna Ferrari, Annalisa Lonetti, Cristina Papayannidis, Viviana Guadagnuolo, Emanuela Ottaviani, Mariachiara Abbenante, Federica Cattina, Antonella Vitale, Stefania Paolini, Simona Soverini, Sarah Parisi, Francesca Paoloni, BS, Fausto Castagnetti, Marco Vignetti, Robin Foà, Michele Baccarani, Giovanni Martinelli

Blood (2010) 116 (21): 3136.

https://doi.org/10.1182/blood.V116.21.3136.3136

Published: 2010

Journal Articles

Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study

Francesca Romana Mauro, MD, Daniele Armiento, MD, Sonia Orlando, BS, Ilaria Del Giudice, MD, Maria Stefania De Propriis, PhD, Mauro Nanni, PhD, Marilisa Marinelli, PhD, Molica Matteo, Paola Fazi, MD, Francesca Paoloni, BS, Graziosi Antonietta, Laura Collada, Anna Guarini, PhD, Robin Foà, MD

Blood (2010) 116 (21): 1377.

https://doi.org/10.1182/blood.V116.21.1377.1377

Published: 2010

Journal Articles

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Blood (2010) 116 (17): 3171–3179.

https://doi.org/10.1182/blood-2010-03-276196

Published: 2010

Journal Articles

PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.

Blood (2009) 114 (22): 12.

https://doi.org/10.1182/blood.V114.22.12.12

Published: 2009

Journal Articles

Distribution of Genetic and Molecular Prognostic Markers in Young Patients with Chronic Lymphocytic Leukemia (CLL) in Different Phases of the Disease.

Ilaria Del Giudice, Francesca Romana Mauro, Mauro Nanni, Rita Barzotti, Maria Stefania De Propris, Sara Raponi, Simona Santangelo, Marilisa Marinelli, Nadia Peragine, Daniele Armiento, Francesca Paoloni, Anna Guarini, Robin Foà

Blood (2009) 114 (22): 4373.

https://doi.org/10.1182/blood.V114.22.4373.4373

Published: 2009

Journal Articles

IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.

Blood (2009) 114 (22): 912.

https://doi.org/10.1182/blood.V114.22.912.912

Published: 2009

Journal Articles

A Prospective Study of Young Chronic Lymphocytic Leukemia (CLL) Patients Investigated at Diagnosis: Distribution and Clinical Significance of Prognostic Factors

Ilaria Del Giudice, Francesca Romana Mauro, Maria Stefania De Propris, Simona Santangelo, Marilisa Marinelli, Nadia Peragine, Valeria Di Maio, Mauro Nanni, Francesca Mancini, Daniele Armiento, Luisa Quattrocchi, Francesca Paoloni, Anna Guarini, Robert Foa

Blood (2008) 112 (11): 3121.

https://doi.org/10.1182/blood.V112.11.3121.3121

Published: 2008

NARROW

The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study)

Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study

Short Course of Bortezomib in Anemic Patients with Refractory or Relapsed Cold Agglutinin Disease. a Phase II Prospective Study By the Gimema Group

Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms

Autopsy Analysis On Epidemiology and Site of Involvement Of Invasive Fungal Infections (IFI) In Hematological Malignancies : A Retrospective Study at Hematologic Tertiary Care Department

Clinical Relevance of an Extended Diagnostic Work-Out in Patients with Primary Autoimmune Amolytic Anemia (AIHA)

Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112

The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients

Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.

Distribution of Genetic and Molecular Prognostic Markers in Young Patients with Chronic Lymphocytic Leukemia (CLL) in Different Phases of the Disease.

IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.

A Prospective Study of Young Chronic Lymphocytic Leukemia (CLL) Patients Investigated at Diagnosis: Distribution and Clinical Significance of Prognostic Factors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only